We describe herein the European Reference Network on Rare Endocrine Conditions clinical practice guideline on diagnosis and management of familial forms of hyperaldosteronism. The guideline panel consisted of 10 experts in primary aldosteronism, endocrine hypertension, paediatric endocrinology, and cardiology as well as a methodologist. A systematic literature search was conducted, and because of the rarity of the condition, most recommendations were based on expert opinion and small patient series. The guideline includes a brief description of the genetics and molecular pathophysiology associated with each condition, the patients to be screened, and how to screen. Diagnostic and treatment approaches for patients with genetically determined diagnosis are presented. The recommendations apply to patients with genetically proven familial hyperaldosteronism and not to families with more than one case of primary aldosteronism without demonstration of a responsible pathogenic variant.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejendo/lvae041DOI Listing

Publication Analysis

Top Keywords

familial hyperaldosteronism
8
european reference
8
reference network
8
network rare
8
rare endocrine
8
endocrine conditions
8
conditions clinical
8
clinical practice
8
practice guideline
8
primary aldosteronism
8

Similar Publications

Article Synopsis
  • Primary aldosteronism (PA) is a significant cause of hypertension, and familial hyperaldosteronism type 1 (FH-1) is a hereditary form that can lead to severe health issues, making early detection important.
  • A study analyzed genetic testing data for FH-1 in New Zealand from April 2010 to October 2023, revealing that only 147 tests were conducted, with a positive result in 12.9% of cases and significant variations in testing rates by region.
  • Although testing rates for FH-1 have increased over the years, they are still considered low, indicating a need for more awareness and testing, especially for individuals diagnosed with PA at a young age or those with a family
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze genetic testing rates for familial hyperaldosteronism (FH) in patients with primary aldosteronism (PA) within the SPAIN-ALDO Registry and to describe the clinical aspects of these patients.
  • Out of 855 patients with PA, only 25 (3%) underwent genetic testing for FH, with complete results for just 24, highlighting a significant gap in testing as only 14% met appropriate criteria for genetic evaluation.
  • The findings indicate that FH is rare, accounting for only 0.2% of PA cases in the registry, though it might be more prevalent (up to 4%) in patients suspected of having the condition, illustrating the need for increased genetic assessment in
View Article and Find Full Text PDF

Monogenic Hypertension Linked to the Renin-Angiotensin-Aldosterone System.

Anatol J Cardiol

June 2024

Division of General Internal Medicine, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Türkiye;Hacettepe University, Center for Genomics and Rare Diseases, Ankara, Türkiye.

Mendelian forms of renin-angiotensin-aldosterone system (RAAS)-related hypertension, commonly referred to as monogenic hypertension, represent a rare but significant subset of hypertensive disorders characterized by genetic mutations that disrupt the normal physiological mechanisms of blood pressure regulation. This review focuses on elucidating the germline mutations affecting RAAS pathways that lead to distinct forms of heritable hypertension. By understanding the pathophysiological basis of conditions such as Gordon's syndrome, Liddle syndrome, congenital adrenal hyperplasia, and familial hyperaldosteronism types, this review aims to highlight the unique clinical features, diagnostic challenges, and therapeutic implications associated with these disorders.

View Article and Find Full Text PDF

Primary aldosteronism is the most common cause of secondary hypertension, which is caused by increased aldosterone secretion in the adrenal cortex and contains many subtypes, among which familial hyperaldosteronism is relatively rare. Familial hyperaldosteronism can be divided into four subtypes based on its clinical manifestations and mutated genes: FH-I , FH-II , FH-III , and FH-IV . This article reports on three patients with FH-IV: a mother and her two sons.

View Article and Find Full Text PDF

KCNJ5 mutations in familial and non-familial primary aldosteronism.

Eur J Endocrinol

June 2024

Department of Endocrinology-Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!